Semin Reprod Med 2003; 21(4): 339-352
DOI: 10.1055/s-2004-815590
Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Disorders of Pubertal Development: Precocious Puberty

Nirupama Kakarla, Karen D. Bradshaw
  • Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas
Further Information

Publication History

Publication Date:
14 January 2004 (online)

ABSTRACT

Puberty is a complex developmental process culminating in sexual maturity. This transitional period begins in late childhood and is characterized by maturation of the hypothalamic-pituitary-gonadal axis, the appearance of secondary sexual characteristics, acceleration of growth, and, ultimately, the capacity for fertility. Significant endocrinologic changes accompany these developmental events. Disorders of pubertal development may occur at any of the steps of the maturational process leading to either precocious or delayed puberty. A thorough understanding of the normal pubertal process is important to the accurate diagnosis and treatment of pubertal disorders.

REFERENCES

  • 1 Plant T M. Puberty in primates. In: Knobil E, Neill JD, eds. The Physiology of Reproduction 2nd ed. New York: Raven Press 1994: 453-485
  • 2 Bradshaw K D, Quigley C A. Disorders of pubertal development. In: Jameson JL, ed. Principles of Molecular Medicine Totowa, NJ: Humana Press 1998: 569-580
  • 3 Kappy M S, Ganong C S. Advances in the treatment of precocious puberty.  Adv Pediatr . 1994;  41 223-261
  • 4 Laue L, Jones J, Barnes K M. Treatment of familial male precocious puberty with spironolactone, testolactone, and deslorelin.  J Clin Endocrinol Metab . 1993;  76 151-155
  • 5 Zachman M, Prader A, Sobel E H. Pubertal growth in patients with complete androgen insensitivity: indirect evidence for the importance of estrogen in girls.  J Pediatr . 1986;  108 694-697
  • 6 Smith E P, Boyd J, Frank G R. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man.  N Engl J Med . 1994;  331 1056-1061
  • 7 Winter J SD, Hughes I A, Reyes F I, Faiman C. Pituitary-gonadal relations in infancy: 2. Patterns of serum gonadal concentrations in man from birth to two years of age.  J Clin Endocrinol Metab . 1976;  42 679-686
  • 8 Palmert M R, Boepple P A. Variations in the timing of puberty: clinical spectrum and genetic investigation.  J Clin Endocrinol Metab . 2001;  86 2364-2368
  • 9 Kalantaridou S N, Chrousos G P. Monogenic disorders of puberty.  J Clin Endocrinol Metab . 2002;  87 2481-2494
  • 10 Hillard P JA. Menstruation in young girls: a clinical perspective.  Obstet Gynecol . 2002;  99 655-662
  • 11 Balducci R, Boscherini B, Mangiantini A, Morellini, Toscano V. Isolated precocious pubarche: an approach.  J Clin Endocrinol Metab . 1994;  79 582-589
  • 12 Pescovitz O H, Comite F, Hench K. The NIH experience with precocious puberty: diagnostic subgroups and response to short-term luteinizing hormone releasing hormone analogue therapy.  J Pediatr . 1986;  108 47-54
  • 13 Burstein S. Editorial: growth disorders after cranial radiation in childhood.  J Clin Endocrinol Metab . 1994;  78 1280-1281
  • 14 Ogilvy-Stuart A L, Clayton P E, Shalet S M. Cranial irradiation and early puberty.  J Clin Endocrinol Metab . 1994;  78 1282-1286
  • 15 Junier M P, Hill D F, Costa M E, Felder S, Ojeda S R. Hypothalamic lesions that induce female precocious puberty activate glial expression of the epidermal growth factor receptor gene: differential regulation of alternatively spliced transcripts.  J Neurosci . 1993;  13 703-713
  • 16 Klein K O. Precocious puberty: who has it?.  <~>Who should be treated? J Clin Endocrinol Metab . 1999;  84 411-414
  • 17 Lee P A. Advances in the management of precocious puberty.  Clin Pediatr (Phila) . 1994;  33 54-61
  • 18 Paul D, Conte F A, Grumbach M M, Kaplan S L. Long term effect of gonadotropin-releasing hormone agonists therapy on final and near-final height in 26 children with true precocious puberty treated at a median age of less than 5 years.  J Clin Endocrinol Metab . 1995;  80 546-551
  • 19 Van der Sluis M I, Boot A M, Krenning E P, Drop S LS, de Muinck Keizer-Schrama S M P F. Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during, and after cessation of GnRH agonist therapy.  J Clin Endocrinol Metab . 2002;  87 506-512
  • 20 Neely E K, Bachrach L K, Hintz R L. Bone mineral density during treatment of central precocious puberty.  J Pediatr . 1995;  127 819-822
  • 21 Shankar R R, Pescovitz O H. Precocious puberty.  Adv Endocrinol Metab . 1995;  6 55-89
  • 22 Lampit M, Golander A, Guttmann H, Hochberg Z. Estrogen mini-dose replacement during GnRH agonist therapy in central precocious puberty: a pilot study.  J Clin Endocrinol Metab . 2002;  87 687-690
  • 23 Feuillan P P, Foster C M, Pescovitz O H. Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone.  N Engl J Med . 1986;  315 1115-1119
  • 24 Holland F J, Fishman L, Bailey J D, Fazekas A T. Ketoconazole in the management of precocious puberty not responsive to LHRH analogue therapy.  N Engl J Med . 1985;  312 1023-1028
  • 25 Schwindinger W F, Francomano C A, Levine M A. Identification of a mutation in gene encoding the α subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome.  Proc Natl Acad Sci USA . 1992;  89 5152-5156
  • 26 Furui K, Suganuma N, Tsukahara S-I. Identification of two point mutations in the gene coding luteinizing hormone (LH) β-subunit, associated with immunologically anomalous LH variants.  J Clin Endocrinol Metab . 1994;  78 107-113
  • 27 Kawate N, Kletter G B, Wilson B E, Netzloff M L, Menon K MJ. Identification of constitutively activating mutation of the luteinising hormone receptor in a family with male limited gonadotrophin independent precocious puberty (testotoxicosis).  J Med Genet . 1995;  32 553-554
  • 28 Shenker A. G protein-coupled receptor structure and function: the impact of disease-causing mutations.  Baillieres Clin Endocrinol Metab . 1995;  9 427-451
  • 29 Shenker A, Laue L, Kosui S, Merendino Jr J J, Minegishi T, Cutler Jr B G. A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty.  Nature . 1993;  365 652-654
  • 30 Kosugi S, Van Dop C, Geffner M E. Characterization of heterogeneous mutations causing constitutive activation of the luteinizing hormone receptor in familial male precocious puberty.  Hum Mol Genet . 1995;  4 183-188
  • 31 Latronico A C, Anasti J, Arnhold I J. A novel mutation of the luteinizing hormone receptor gene causing male gonadotropin-independent precocious puberty.  J Clin Endocrinol Metab . 1995;  80 2490-2494
  • 32 Laue L, Chan W Y, Hsueh A J. Genetic heterogeneity of constitutively activating mutations of the human luteinizing hormone receptor in familial male-limited precocious puberty.  Proc Natl Acad Sci USA . 1995;  92 1906-1910
  • 33 Choong C S, Fuller P J, Chu S. Sertoli-Leydig cell tumor of the ovary, a rare cause of precocious puberty in a 12 month-old infant.  J Clin Endocrinol Metab . 2002;  87 49-56
    >